XML 23 R6.htm IDEA: XBRL DOCUMENT v3.25.4
Consolidated Statements of Changes in Stockholders’ Equity - USD ($)
$ in Thousands
Total
Secondary Equity Public Offering
Common Stock
Common Stock
Secondary Equity Public Offering
Additional Paid-In Capital
Additional Paid-In Capital
Secondary Equity Public Offering
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2022     61,037,000          
Beginning balance at Dec. 31, 2022 $ 209,581   $ 6   $ 930,425   $ (1,086) $ (719,764)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of shares of common stock, net of issuance costs (in shares)     1,250,000 33,425,000        
Issuance of shares of common stock, net of issuance costs 3,136 $ 95,765 $ 0 $ 3 3,136 $ 95,762    
Issuance of common stock upon the exercise of stock options (in shares)     348,000          
Issuance of common stock upon the exercise of stock options 1,247       1,247      
Issuance of common stock upon the vesting of restricted stock units (in shares)     440,000          
Lapse of repurchase rights related to common stock issued pursuant to early exercises (in shares)     15,000          
Lapse of repurchasing rights related to common stock issued pursuant to early exercises 0       0      
Shares issued pursuant to the ESPP (in shares)     272,000          
Shares issued pursuant to the ESPP 1,175       1,175      
Stock-based compensation expense 38,813       38,813      
Unrealized gain (loss) on marketable securities 1,186           1,186  
Foreign currency translation adjustment (96)           (96)  
Net loss (262,140)             (262,140)
Ending balance (in shares) at Dec. 31, 2023     96,787,000          
Ending Balance at Dec. 31, 2023 88,667   $ 9   1,070,558   4 (981,904)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of shares of common stock, net of issuance costs (in shares)       18,158,000        
Issuance of shares of common stock, net of issuance costs   $ 161,682   $ 3   $ 161,679    
Issuance of common stock upon the exercise of stock options (in shares)     649,000          
Issuance of common stock upon the exercise of stock options 2,807       2,807      
Issuance of common stock upon the vesting of restricted stock units (in shares)     1,720,000          
Shares issued pursuant to the ESPP (in shares)     534,000          
Shares issued pursuant to the ESPP 1,713       1,713      
Stock-based compensation expense 42,722       42,722      
Unrealized gain (loss) on marketable securities 219           219  
Foreign currency translation adjustment (230)           (230)  
Net loss (140,039)             (140,039)
Ending balance (in shares) at Dec. 31, 2024     117,848,000          
Ending Balance at Dec. 31, 2024 $ 157,541   $ 12   1,279,479   (7) (1,121,943)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                
Issuance of common stock upon the exercise of stock options (in shares) 714,125   714,000          
Issuance of common stock upon the exercise of stock options $ 4,597       4,597      
Issuance of common stock upon the vesting of restricted stock units (in shares)     2,271,000          
Exercise of pre-funded warrants (in shares)     2,285,000          
Shares issued pursuant to the ESPP (in shares)     215,000          
Shares issued pursuant to the ESPP 2,376       2,376      
Stock-based compensation expense 41,143       41,143      
Unrealized gain (loss) on marketable securities (206)           (206)  
Foreign currency translation adjustment 169           169  
Net loss (16,141)             (16,141)
Ending balance (in shares) at Dec. 31, 2025     123,333,000          
Ending Balance at Dec. 31, 2025 $ 189,479   $ 12   $ 1,327,595   $ (44) $ (1,138,084)